Pacira Pharmaceuticals, Inc.
) recently announced that the data from the second IMPROVE study
on its marketed product Exparel was published online in the
Journal of Pain Research.
This study was conducted on 27 adults who underwent planned
ileostomy reversal procedures. Of the 27, 16 patients were
enrolled in the Exparel-based multimodal group. The remaining
patients were enrolled in the opioid-based group.
Results from the study revealed a 2.1 day reduction in median
length of hospital stay, $2,800 reduction in mean hospitalization
costs and 92 mg reduction in mean opioid consumption in patients
under the Exparel group compared to the opioid-based treatment
This was the second open-label phase IV study under the
IMPROVE program. The IMPROVE studies evaluate the differences in
postsurgical opioid use and health economic outcomes between
patients receiving Exparel and those receiving a standard
opioid-based analgesic regimen.
Data from the first IMPROVE study was published in the Journal
of Pain Research in Nov 2012. This study showed a 2.9 day
reduction in median length of hospital stay, $3,084 reduction in
mean hospitalization costs and 58 mg reduction in mean opioid
consumption in patients under the Exparel group as compared to
the opioid-based treatment arm.
Exparel is currently approved by the US Food and Drug
Administration (FDA) for administration into the surgical site to
produce postsurgical analgesia. The drug was approved by the FDA
in the final quarter of 2011 and launched in Apr 2012.
We note the pipeline at Pacira includes DepoNSAID for
infiltration and intraarticular indication and DepoMethotrexate
for rheumatoid arthritis and oncology.
Pacira carries a Zacks Rank #2 (Buy).
Vertex Pharmaceuticals Inc.
) look equally attractive with a ZacksRank #2.
Jazz Pharmaceuticals plc
) appears to be better positioned with a ZacksRank #1 (Strong
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
PACIRA PHARMACT (PCRX): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
VERTEX PHARM (VRTX): Free Stock Analysis
To read this article on Zacks.com click here.